Elanco Animal Health projects earnings growth through 2028
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
Elanco Animal Health Inc's stock declined by 3.83% and hit a 20-day low amid broader market gains.
The company recently provided earnings forecasts for the years 2026 to 2028, anticipating low double-digit adjusted earnings per share. This announcement may influence investor sentiment and stock performance in the animal health sector.
Investors will be closely monitoring Elanco's performance as it navigates through market challenges, especially in light of its projections and the overall market conditions.
Analyst Views on ELAN
Wall Street analysts forecast ELAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is 25.50 USD with a low forecast of 22.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 24.120
Low
22.00
Averages
25.50
High
30.00
Current: 24.120
Low
22.00
Averages
25.50
High
30.00
About ELAN
Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
